AFT PHARMACEUTICALS LIMITED — Director's Dealing 2020

Jun 16, 2020

==> picture [114 x 29] intentionally omitted <==

Ongoing Disclosure Notice Disclosure of Directors and Senior Managers Relevant Interests Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited;and
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Date this disclosure made:		17-Jun-20
Date of last disclosure:		13-Dec-18
Director or senior managergivingdisclosure
Full name(s):		David Flacks
Name of listed issuer:		AFT Pharmaceuticals Limited(AFT)
Name of related bodycorporate(if applicable):		Not applicable
Position held in listed issuer:		Director
Summary of acquisition or disposal of relevant interest(excluding specified derivatives)
Class of affectedquoted financialproducts:		Fully-Paid OrdinaryShares in AFT
Nature of the affected relevant interest(s):		Joint registered holder and beneficial owner of ordinary shares
For that relevant interest-
Number held in class before acquisition or disposal:		145,431
Number held in class after acquisition or disposal:		165,431
Current registered holder(s):		Unknown
Registered holder(s) once transfers are registered:		David Mark Flacks & Adina Rita Betty Halpern as trustees of Waitemata FamilyTrust
Details of transactionsgiving rise to acquisition or disposal
Total number of transactions to which notice relates:		1
Details of transactions requiring disclosure-
Date of transaction:		15-Jun-20
Nature of transaction:		On-market acquisition of ordinaryshares
Name of anyotherpartyorparties to the transaction(if known):		Unknown
The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration:		NZ$3.866475per share / $77,329.50
Number of financialproducts to which the transaction related:		20,000
If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details—
Whether relevant interests were acquired or disposed of duringa closedperiod:		No
Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closedperiod:		Not applicable
Date of theprior written clearance(if any):		Not applicable
Summary of other relevant interests after acquisition or disposal: Class ofquoted financialproducts: Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative: Details of derivative,-
		Not applicable
		Not applicable
		Not applicable
		Not applicable
		Not applicable
The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):		Not applicable
A statement as to whether the derivative is cash settled orphysicallysettled:		Not applicable
Maturitydate of the derivative(if any):		Not applicable
Expirydate of the derivative(if any):		Not applicable
Theprice's specified terms(if any):		Not applicable
Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products:		Not applicable
_For that derivative relevant interest,- _
Parties to the derivative:		Not applicable
If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:		Not applicable
Certification I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am dulyauthorised to make this disclosure byallpersons for whom it is made. Signature of director or officer: Date of signature:
I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am dulyauthorised to make this disclosure byallpersons for whom it is made.
Signature of director or officer:
Date of signature:		17-Jun-20

==> picture [534 x 46] intentionally omitted <==

==> picture [54 x 120] intentionally omitted <==